{
    "Clinical Trial ID": "NCT00712985",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid 5 mg IV",
        "  Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Postmenopausal women with Stage I, II or IIIa breast cancer being treated with a non-steroidal Aromatase Inhibitor (AI) .Negative bone scan (no bone metastases).",
        "  Calculated creatinine clearance > 40 ml/min",
        "  Documented T score of less than or equal to -1.5 on Dual Energy X-ray Absorptiionmetry (DXA) scan at the lumbar spine or femoral neck within 3 months prior to screening.",
        "  Urine NTx > 50 nano moles(nM)based on second morning void.",
        "  Signed informed consent.",
        "  Ambulatory patients at least 18 years of age.",
        "  Eastern Cooperative Oncology Group (ECOG)0-2.",
        "  Ability to comply with trial requirements.",
        "Exclusion Criteria:",
        "  Bone Metastases.",
        "  Any woman of child bearing potential.",
        "  Patients with fractures occurring within three months prior to randomization. - Greater than a 2+ protein on urine dipstick without evidence of contamination or bacteriuria (may be repeated one time, at least a day apart).",
        "  Calculated creatinine clearance less than 30 mL/min at screening.",
        "  Serum calcium > 2.75 mmol/L (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL).",
        "  Liver Function tests (LFT)> 2.0 x upper limit of normal (ULN).",
        "  Serum alkaline phosphatase > 1.5 x ULN. History of hypersensitivity to bisphosphonates.",
        "  Evidence of vitamin D deficiency (serum 25-(OH) D of less than 15 ng/ml).",
        "  History of uveitis or iritis, except when secondary to trauma, and must have resolved > 2 years prior to entry.",
        "  A history of invasive malignancy of any organ system, treated or untreated, within the past 12 months prior to screening; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, Ductal Carcinoma in-situ (DCIS) that has been surgically removed, and Carcinoma in-situ (CIS) of the uterine cervix that has been surgically removed.",
        "  Previous major solid organ transplant recipient or on a transplant waiting list.",
        "  Treatment with any investigational drug within 30 days prior to randomization.",
        "  History of hyperparathyroidism, hypoparathyroidism, Osteogenesis imperfecta, Paget's disease or any metabolic bone disease other than osteoporosis.",
        "  Any medical condition which would interfere with the action of the study drug or limit life expectancy to less than 6 months.",
        "  Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial.",
        "  Prior treatment with IV bisphosphonates within the last 2 years.",
        "  Previous use of oral bisphosphonates within the past 2 years (unless used for less than 8 weeks*). *NOTE: If used less than 8 weeks, the washout period is 6 months.",
        "  Treatment with raloxifene, calcitonin, tibolone or hormone replacement therapy. The washout period for these medications is 6 months prior to randomization.",
        "  Any treatment with strontium ranelate, samarium, sodium fluoride or parathyroid hormone.",
        "  Use of systemic high dose corticosteroids at an average dose of > 7.5 mg per day of oral prednisone or equivalent for a period of three months or more prior to screening.",
        "  Known hypersensitivity to zoledronic acid or other bisphosphonates.",
        "  Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.",
        "  Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 Months",
        "  17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12.",
        "  Time frame: One year",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid 5 mg IV",
        "  Arm/Group Description: Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).",
        "  Overall Number of Participants Analyzed: 13",
        "  Measure Type: Number",
        "  Unit of Measure: participants  13"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/17 (0.00%)"
    ]
}